

# Thierry Soussi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1525443/publications.pdf>

Version: 2024-02-01

192  
papers

15,560  
citations

14655

66  
h-index

17592

121  
g-index

228  
all docs

228  
docs citations

228  
times ranked

14942  
citing authors

#	ARTICLE	IF	CITATIONS
1	Database of p53 gene somatic mutations in human tumors and cell lines. <i>Nucleic Acids Research</i> , 1994, 22, 3551-5.	14.5	646
2	Assessing TP53 status in human tumours to evaluate clinical outcome. <i>Nature Reviews Cancer</i> , 2001, 1, 233-239.	28.4	587
3	TP53 tumor suppressor gene: A model for investigating human mutagenesis. <i>Genes Chromosomes and Cancer</i> , 1992, 4, 1-15.	2.8	508
4	Structural aspects of the p53 protein in relation to gene evolution. <i>Oncogene</i> , 1990, 5, 945-52.	5.9	469
5	p53 Antibodies in the sera of patients with various types of cancer: a review. <i>Cancer Research</i> , 2000, 60, 1777-88.	0.9	429
6	Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. <i>Nucleic Acids Research</i> , 1996, 24, 141-146.	14.5	422
7	Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. <i>Cell Reports</i> , 2019, 28, 1370-1384.e5.	6.4	382
8	The TP53 Colorectal Cancer International Collaborative Study on the Prognostic and Predictive Significance of p53 Mutation: Influence of Tumor Site, Type of Mutation, and Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2005, 23, 7518-7528.	1.6	331
9	Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm. <i>Cancer Cell</i> , 2007, 12, 303-312.	16.8	316
10	Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. <i>Nucleic Acids Research</i> , 1997, 25, 151-157.	14.5	301
11	TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade. <i>Human Mutation</i> , 2014, 35, 672-688.	2.5	294
12	Serum p53 antibodies as early markers of lung cancer. <i>Nature Medicine</i> , 1995, 1, 701-702.	30.7	293
13	Multifactorial analysis of p53 alteration in human cancer: A review. <i>International Journal of Cancer</i> , 1994, 57, 1-9.	5.1	287
14	APC gene: database of germline and somatic mutations in human tumors and cell lines. <i>Nucleic Acids Research</i> , 1996, 24, 121-124.	14.5	286
15	Rapid and Sensitive p53 Alteration Analysis in Biopsies from Lung Cancer Patients Using a Functional Assay and A Universal Oligonucleotide Array. <i>Clinical Cancer Research</i> , 2004, 10, 3479-3489.	7.0	277
16	Mutant p53 protein localized in the cytoplasm inhibits autophagy. <i>Cell Cycle</i> , 2008, 7, 3056-3061.	2.6	262
17	The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation. <i>Annals of the New York Academy of Sciences</i> , 2000, 910, 121-139.	3.8	260
18	p53 mutation heterogeneity in cancer. <i>Biochemical and Biophysical Research Communications</i> , 2005, 331, 834-842.	2.1	232

#	ARTICLE	IF	CITATIONS
19	p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis. <i>Human Mutation</i> , 2000, 15, 105-113.	2.5	231
20	TP53: an oncogene in disguise. <i>Cell Death and Differentiation</i> , 2015, 22, 1239-1249.	11.2	227
21	The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. <i>Cancer Research</i> , 1992, 52, 6380-4.	0.9	221
22	p53 alterations in human cancer: more questions than answers. <i>Oncogene</i> , 2007, 26, 2145-2156.	5.9	210
23	Structural Aspects of the p53 Protein in Relation to Gene Evolution: A Second Look. <i>Journal of Molecular Biology</i> , 1996, 260, 623-637.	4.2	201
24	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation.. <i>EMBO Journal</i> , 1994, 13, 3496-3504.	7.8	193
25	UMD (Universal Mutation Database): A generic software to build and analyze locus-specific databases. <i>Human Mutation</i> , 2000, 15, 86-94.	2.5	184
26	p53 Alterations Predict Tumor Response to Neoadjuvant Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Series. <i>Journal of Clinical Oncology</i> , 2000, 18, 1465-1473.	1.6	178
27	Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment. <i>Human Mutation</i> , 2014, 35, 756-765.	2.5	170
28	ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation. <i>Leukemia</i> , 2018, 32, 1070-1080.	7.2	149
29	Increase of spontaneous intrachromosomal homologous recombination in mammalian cells expressing a mutant p53 protein. <i>Oncogene</i> , 1997, 14, 1117-1122.	5.9	143
30	Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. <i>British Journal of Cancer</i> , 1994, 69, 809-816.	6.4	141
31	Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. <i>Cancer Research</i> , 1993, 53, 5872-6.	0.9	141
32	Cloning and characterization of a cDNA from <i>Xenopus laevis</i> coding for a protein homologous to human and murine p53. <i>Oncogene</i> , 1987, 1, 71-8.	5.9	140
33	Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. <i>Lancet, The</i> , 1995, 345, 621-622.	13.7	138
34	The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. <i>Nucleic Acids Research</i> , 2013, 41, D962-D969.	14.5	138
35	The UMD-p53 database: New mutations and analysis tools. <i>Human Mutation</i> , 2003, 21, 176-181.	2.5	136
36	Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. <i>Nature Reviews Cancer</i> , 2006, 6, 83-90.	28.4	134

#	ARTICLE	IF	CITATIONS
37	TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. <i>Leukemia</i> , 2010, 24, 2072-2079.	7.2	134
38	p53 gene mutation: software and database. <i>Nucleic Acids Research</i> , 1998, 26, 200-204.	14.5	132
39	Cancer and the heat shock response. <i>European Journal of Cancer</i> , 1994, 30, 1884-1891.	2.8	127
40	Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. <i>Human Mutation</i> , 2005, 25, 6-17.	2.5	127
41	Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. <i>Gastroenterology</i> , 2002, 123, 492-504.	1.3	126
42	The UMD TP53 database and website: update and revisions. <i>Human Mutation</i> , 2006, 27, 14-20.	2.5	125
43	Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. <i>Haematologica</i> , 2010, 95, 1973-1976.	3.5	124
44	APC gene: database of germline and somatic mutations in human tumors and cell lines. <i>Nucleic Acids Research</i> , 1998, 26, 269-270.	14.5	119
45	Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint. <i>Oncogene</i> , 1999, 18, 3553-3563.	5.9	116
46	Nucleotide sequence of a cDNA encoding the rat p53 nuclear oncoprotein. <i>Nucleic Acids Research</i> , 1988, 16, 11384-11384.	14.5	111
47	UMD (Universal Mutation Database): 2005 update. <i>Human Mutation</i> , 2005, 26, 184-191.	2.5	101
48	The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. <i>Trends in Immunology</i> , 1996, 17, 354-356.	7.5	96
49	Regulation of Mutant p53 Temperature-sensitive DNA Binding. <i>Journal of Biological Chemistry</i> , 1996, 271, 25468-25478.	3.4	94
50	Significance of TP53 mutations in human cancer: A critical analysis of mutations at CpG dinucleotides. <i>Human Mutation</i> , 2003, 21, 192-200.	2.5	94
51	p53-dependent pathway of radio-induced apoptosis is altered in Fanconi anemia. <i>Oncogene</i> , 1995, 10, 9-17.	5.9	94
52	Epithelial HBL-100 cell line derived from milk of an apparently healthy woman harbours SV40 genetic information. <i>Experimental Cell Research</i> , 1985, 160, 83-94.	2.6	92
53	Can we predict solar ultraviolet radiation as the causal event in human tumours by analysing the mutation spectra of the p53 gene?. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1994, 307, 375-386.	1.0	92
54	Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. <i>Annals of Oncology</i> , 2006, 17, 842-847.	1.2	92

#	ARTICLE	IF	CITATIONS
55	Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. <i>Cancer Biology and Therapy</i> , 2008, 7, 699-708.	3.4	91
56	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. <i>EMBO Journal</i> , 1994, 13, 3496-504.	7.8	91
57	Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. <i>European Journal of Immunology</i> , 1995, 25, 1765-1769.	2.9	90
58	Analysis of p53 Serum Antibodies in Patients With Head and Neck Squamous Cell Carcinoma. <i>Journal of the National Cancer Institute</i> , 1996, 88, 1228-1233.	6.3	87
59	Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. <i>Blood</i> , 1997, 90, 766-75.	1.4	83
60	p53 gene mutation: software and database. <i>Nucleic Acids Research</i> , 1996, 24, 147-150.	14.5	82
61	Data-driven unbiased curation of the <i>TP53</i> tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9551-9556.	7.1	75
62	Genetic alterations in localized prostate cancer: Identification of a common region of deletion on chromosome arm 18q. <i>Genes Chromosomes and Cancer</i> , 1994, 11, 119-125.	2.8	74
63	p53 antibodies in the sera of lung cancer patients: Comparison with p53 mutation in the tumour tissue. <i>International Journal of Cancer</i> , 1995, 64, 176-181.	5.1	74
64	Detection and monitoring of serum p53 antibodies in patients with colorectal cancer.. <i>Gut</i> , 1997, 40, 356-361.	12.1	73
65	Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan. <i>Cell Reports</i> , 2019, 28, 132-144.e3.	6.4	72
66	Rainbow trout p53: cDNA cloning and biochemical characterization. <i>Gene</i> , 1992, 112, 241-245.	2.2	71
67	p53 Mutation as a Genetic Trait of Typical Medullary Breast Carcinoma. <i>Journal of the National Cancer Institute</i> , 1999, 91, 641-643.	6.3	71
68	Recommended Guidelines for Validation, Quality Control, and Reporting of <i>TP53</i> Variants in Clinical Practice. <i>Cancer Research</i> , 2017, 77, 1250-1260.	0.9	68
69	Meta-analysis of the p53 Mutation Database for Mutant p53 Biological Activity Reveals a Methodologic Bias in Mutation Detection. <i>Clinical Cancer Research</i> , 2006, 12, 62-69.	7.0	67
70	Effects of Electrical Brainstem Stimulation on Tinnitus. <i>Acta Oto-Laryngologica</i> , 1994, 114, 135-140.	0.9	63
71	Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. <i>Clinical Cancer Research</i> , 1998, 4, 1359-66.	7.0	63
72	Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients. <i>Journal of Pathology</i> , 2000, 192, 52-57.	4.5	61

#	ARTICLE	IF	CITATIONS
73	TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade. <i>Advances in Cancer Research</i> , 2011, 110, 107-139.	5.0	61
74	Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. <i>Oncogene</i> , 1994, 9, 3689-94.	5.9	61
75	Splice mutations in the p53 gene: case report and review of the literature. <i>Human Mutation</i> , 2003, 21, 101-102.	2.5	60
76	Database and software for the analysis of mutations in the human p53 gene. <i>Cancer Research</i> , 1994, 54, 4454-60.	0.9	58
77	The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. <i>Gene</i> , 2002, 282, 207-214.	2.2	57
78	Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases.. <i>Gut</i> , 1995, 36, 455-458.	12.1	55
79	Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. <i>Nature Communications</i> , 2019, 10, 5385.	12.8	53
80	SQUAMOUS CELL CARCINOMAS AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION FOR APLASTIC ANEMIA. <i>Transplantation</i> , 1998, 66, 667-670.	1.0	53
81	p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 1342-1346.	7.1	51
82	The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. <i>Trends in Molecular Medicine</i> , 1996, 2, 32-37.	2.6	51
83	Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. <i>Oncogene</i> , 1994, 9, 2071-6.	5.9	50
84	Databases and software for the analysis of mutations in the human p53 gene, human hpvt gene and both the lacI and lacZ gene in transgenic rodents. <i>Nucleic Acids Research</i> , 1998, 26, 198-199.	14.5	49
85	P53 Gene Alterations in Human Tumors: Perspectives for Cancer Control. <i>Recent Results in Cancer Research</i> , 1997, 143, 369-389.	1.8	48
86	The history of p53. <i>EMBO Reports</i> , 2010, 11, 822-826.	4.5	47
87	Stabilization and Expression of High Levels of p53 during Early Development in <i>Xenopus laevis</i> . <i>Developmental Biology</i> , 1993, 159, 163-172.	2.0	46
88	p53 antibodies in the saliva of patients with squamous cell carcinoma of the oral cavity. , 1998, 78, 390-391.		45
89	DNA-binding properties of the major structural protein of simian virus 40. <i>Journal of Virology</i> , 1986, 59, 740-742.	3.4	43
90	Versatile analysis of multiple macromolecular interactions by SPR imaging: application to p53 and DNA interaction. <i>Oncogene</i> , 2004, 23, 5543-5550.	5.9	42

#	ARTICLE	IF	CITATIONS
91	ATF/CREB site mediated transcriptional activation and p53 dependent repression of the cyclin A promoter. <i>FEBS Letters</i> , 1996, 385, 34-38.	2.8	41
92	Software and database for the analysis of mutations in the human FBN1 gene. <i>Nucleic Acids Research</i> , 1996, 24, 137-140.	14.5	41
93	Emergence and evolution of <i>TP53</i> mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. <i>Haematologica</i> , 2018, 103, e143-e146.	3.5	41
94	Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer. <i>International Journal of Cancer</i> , 2000, 89, 81-86.	5.1	40
95	An endonuclease/ligase based mutation scanning method especially suited for analysis of neoplastic tissue. <i>Oncogene</i> , 2002, 21, 1909-1921.	5.9	40
96	Nucleotide sequence of a cDNA encoding the chicken p53 nuclear oncoprotein. <i>Nucleic Acids Research</i> , 1988, 16, 11383-11383.	14.5	39
97	Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?. <i>Breast Cancer Research and Treatment</i> , 1998, 47, 47-55.	2.5	37
98	The p53 pathway and human cancer. <i>British Journal of Surgery</i> , 2005, 92, 1331-1332.	0.3	37
99	Change of Conformation of the DNA-binding Domain of p53 Is the Only Key Element for Binding of and Interference with p73. <i>Journal of Biological Chemistry</i> , 2003, 278, 10546-10555.	3.4	36
100	Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl $\alpha$ -Ketoglutarate. <i>Cell Reports</i> , 2019, 27, 820-834.e9.	6.4	36
101	Evolutionary conservation of the biochemical properties of p53: specific interaction of <i>Xenopus laevis</i> p53 with simian virus 40 large T antigen and mammalian heat shock proteins 70. <i>Journal of Virology</i> , 1989, 63, 3894-3901.	3.4	36
102	Characterization of a bovine acidic FGF cDNA clone and its expression in brain and retina. <i>FEBS Letters</i> , 1988, 242, 41-46.	2.8	35
103	ThinPrep <sup>®</sup> -processed fine-needle samples of breast are effective material for RNA- and DNA-based molecular diagnosis. <i>Cancer</i> , 2003, 99, 223-232.	4.1	35
104	Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses. <i>Human Mutation</i> , 1996, 7, 202-213.	2.5	34
105	Stimulation of rat liver $\alpha$ - and $\beta$ -type DNA polymerases by an homologous DNA-unwinding protein. <i>FEBS Letters</i> , 1977, 79, 160-164.	2.8	30
106	Serum p53 antibodies: predictors of survival in small-cell lung cancer?. <i>British Journal of Cancer</i> , 2000, 83, 1418-1424.	6.4	30
107	Recommendations for Analyzing and Reporting <i>TP53</i> Gene Variants in the High-Throughput Sequencing Era. <i>Human Mutation</i> , 2014, 35, 766-778.	2.5	29
108	Absence of p53 germ-line mutations in bilateral breast cancer patients. <i>Human Genetics</i> , 1992, 89, 250-2.	3.8	28

#	ARTICLE	IF	CITATIONS
109	Pediatric Cancer Variant Pathogenicity Information Exchange (PeCanPIE): a cloud-based platform for curating and classifying germline variants. <i>Genome Research</i> , 2019, 29, 1555-1565.	5.5	28
110	A functional analysis of p53 during early development of <i>xenopus laevis</i> . <i>Oncogene</i> , 1997, 15, 2191-2199.	5.9	27
111	p53 mutations and resistance to chemotherapy: A stab in the back for p73. <i>Cancer Cell</i> , 2003, 3, 303-305.	16.8	27
112	Databases and software for the analysis of mutations in the human p53 gene, the human hprt gene and both the lacI and lacZ gene in transgenic rodents. <i>Nucleic Acids Research</i> , 1997, 25, 136-137.	14.5	26
113	Molecular Genetic Analysis of p53 Intratumoral Heterogeneity in Human Astrocytic Brain Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 944-954.	1.7	26
114	MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancers. <i>Human Mutation</i> , 2010, 31, 1020-1025.	2.5	26
115	Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene. <i>Cell Death and Differentiation</i> , 2021, 28, 1477-1492.	11.2	26
116	p53 immunolabeling in archival paraffin-embedded tissues: optimal protocol based on microwave heating for eight antibodies on lung carcinomas. <i>Modern Pathology</i> , 1994, 7, 853-9.	5.5	26
117	Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking. <i>Lung Cancer</i> , 2003, 39, 297-301.	2.0	25
118	Database and software for the analysis of mutations at the human p53 gene. <i>Nucleic Acids Research</i> , 1994, 22, 3549-50.	14.5	25
119	The cDNA cloning and immunological characterization of hamster p53. <i>Gene</i> , 1992, 112, 247-250.	2.2	24
120	Databases and software for the analysis of mutations in the human p53 gene, the human hprt gene and the lacZ gene in transgenic rodents. <i>Nucleic Acids Research</i> , 1996, 24, 119-120.	14.5	24
121	Translocation of a Store of Maternal Cytoplasmic c-myc Protein into Nuclei during Early Development. <i>Molecular and Cellular Biology</i> , 1989, 9, 5395-5403.	2.3	24
122	Serum p53 antibodies in correlation to other biological parameters of breast cancer. <i>Cancer Detection and Prevention</i> , 2003, 27, 182-186.	2.1	22
123	Focus on the p53 gene and cancer: Advances in TP53 mutation research. <i>Human Mutation</i> , 2003, 21, 173-175.	2.5	22
124	Seshat: A Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next-generation sequencing. <i>Human Mutation</i> , 2018, 39, 925-933.	2.5	21
125	Harmonized microarray/mutation scanning analysis of TP53 mutations in undissected colorectal tumors. <i>Human Mutation</i> , 2004, 24, 63-75.	2.5	20
126	Synonymous Somatic Variants in Human Cancer Are Not Infamous: A Plea for Full Disclosure in Databases and Publications. <i>Human Mutation</i> , 2017, 38, 339-342.	2.5	20



#	ARTICLE	IF	CITATIONS
127	Anti-apoptotic activity of p53 maps to the COOH-terminal domain and is retained in a highly oncogenic natural mutant. <i>Oncogene</i> , 1999, 18, 4699-4709.	5.9	19
128	Detection of p73 antibodies in patients with various types of cancer: immunological characterization. <i>British Journal of Cancer</i> , 2001, 84, 57-63.	6.4	19
129	TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes. <i>International Journal of Cancer</i> , 2016, 139, 1759-1763.	5.1	18
130	Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations. <i>Haematologica</i> , 2018, 103, e13-e16.	3.5	18
131	Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck. <i>Anticancer Research</i> , 1996, 16, 2385-8.	1.1	18
132	p53 and APC gene mutations: software and databases. <i>Nucleic Acids Research</i> , 1997, 25, 138-138.	14.5	17
133	Regulation of the specific DNA binding activity of <i>Xenopus laevis</i> p53: evidence for conserved regulation through the carboxy-terminus of the protein. <i>Oncogene</i> , 1998, 16, 883-890.	5.9	17
134	Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance. <i>Lung Cancer</i> , 2001, 31, 17-23.	2.0	17
135	High prevalence of cancer-associated TP53 variants in the gnomAD database: A word of caution concerning the use of variant filtering. <i>Human Mutation</i> , 2019, 40, 516-524.	2.5	17
136	<i>Xenopus laevis</i> p53 protein: sequence-specific DNA binding, transcriptional regulation and oligomerization are evolutionarily conserved. <i>Oncogene</i> , 1995, 10, 779-84.	5.9	17
137	Fam83F induces p53 stabilisation and promotes its activity. <i>Cell Death and Differentiation</i> , 2019, 26, 2125-2138.	11.2	16
138	Lack of HIN-1 Methylation Defines Specific Breast Tumor Subtypes Including Medullary Carcinoma of the Breast and BRCA1-Linked Tumors. <i>Cancer Biology and Therapy</i> , 2003, 2, 559-563.	3.4	15
139	Locus-Specific Databases in Cancer: What Future in a Post-Genomic Era? The TP53 LSDB paradigm. <i>Human Mutation</i> , 2014, 35, 643-653.	2.5	15
140	Squaramide-based synthetic chloride transporters activate TFEB but block autophagic flux. <i>Cell Death and Disease</i> , 2019, 10, 242.	6.3	15
141	Advances in carcinogenesis: A historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2011, 1816, 199-208.	7.4	13
142	The TP53 Gene Network in a Postgenomic Era. <i>Human Mutation</i> , 2014, 35, 641-642.	2.5	13
143	Anti-p53 antibodies are rarely detected in serum of patients with rheumatoid arthritis and Sjögren's syndrome. <i>Journal of Rheumatology</i> , 1999, 26, 1672-5.	2.0	13
144	Colorectal Cancer Is Associated with the Presence of Cancer Driver Mutations in Normal Colon. <i>Cancer Research</i> , 2022, 82, 1492-1502.	0.9	13

#	ARTICLE	IF	CITATIONS
145	p53 mutations in BRCA1-associated familial breast cancer. <i>Lancet, The</i> , 1998, 352, 622.	13.7	12
146	Critical residues of epitopes recognized by several anti-p53 monoclonal antibodies correspond to key residues of p53 involved in interactions with the mdm2 protein. <i>Journal of Immunological Methods</i> , 2000, 244, 17-28.	1.4	12
147	Regulation of the cell cycle by p53 after DNA damage in an amphibian cell line. <i>Oncogene</i> , 2001, 20, 3766-3775.	5.9	12
148	Data mining the p53 pathway in the Fugu genome: evidence for strong conservation of the apoptotic pathway. <i>Oncogene</i> , 2003, 22, 5082-5090.	5.9	12
149	Medullary Breast Carcinoma: Prognostic Implications of P53 Expression. <i>International Journal of Biological Markers</i> , 2003, 18, 99-105.	1.8	12
150	Investigation and prediction of the severity of p53 mutants using parameters from structural calculations. <i>FEBS Journal</i> , 2009, 276, 4142-4155.	4.7	12
151	Comprehensive assessment of TP53 loss of function using multiple combinatorial mutagenesis libraries. <i>Scientific Reports</i> , 2020, 10, 20368.	3.3	12
152	Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. <i>Bulletin Du Cancer</i> , 1993, 80, 102-10.	1.6	11
153	3-Methylcholanthrene inactivates the p53 gene in Syrian hamster embryo fibroblasts by inducing a specific intronic point mutation. <i>Cancer Research</i> , 1994, 54, 4502-7.	0.9	11
154	Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA <i>TP53</i> Mutationsâ€”A Perspective from a Real-World Precision Medicine Cohort. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2612-2620.	4.1	10
155	Evolutionary history of the p53 family DNA-binding domain: insights from an <i>Alvinella pompejana</i> homolog. <i>Cell Death and Disease</i> , 2022, 13, 214.	6.3	10
156	Genetic profiling of CLL: a â€”TP53 addictâ€”™ perspective. <i>Cell Death and Disease</i> , 2016, 7, e2042-e2042.	6.3	9
157	Functional characterization of <i>Xenopus laevis</i> p53: evidence of temperature-sensitive transactivation but not of repression. <i>Journal of Virology</i> , 1994, 68, 7178-7187.	3.4	9
158	TP53_PROF: a machine learning model to predict impact of missense mutations in <i>TP53</i> . <i>Briefings in Bioinformatics</i> , 2022, 23, .	6.5	9
159	MUT-TP53: a versatile matrix for TP53 mutation verification and publication. <i>Human Mutation</i> , 2006, 27, 1151-1154.	2.5	7
160	Medullary breast carcinoma: Prognostic implications of p53 expression. <i>International Journal of Biological Markers</i> , 2003, 18, 99-105.	1.8	7
161	A monoclonal antibody against DNA binding helix of p53 protein. <i>Oncogene</i> , 2001, 20, 1398-1401.	5.9	6
162	MDM2-TP53 Crossregulation: An Underestimated Target to Promote Loss of TP53 Function and Cell Survival. <i>Trends in Cancer</i> , 2018, 4, 602-605.	7.4	6

#	ARTICLE	IF	CITATIONS
163	Breast-cancer stromal cells with TP53 mutations. <i>New England Journal of Medicine</i> , 2008, 358, 1635; author reply 1636.	27.0	6
164	Benign SNPs in the Coding Region of <i>TP53</i> : Finding the Needles in a Haystack of Pathogenic Variants. <i>Cancer Research</i> , 2022, 82, 3420-3431.	0.9	6
165	Functional analyses of a unique p53 germline mutant (y236?) associated with a familial brain tumor syndrome. <i>Journal of Clinical Investigation</i> , 1999, 82, 17-22.		5
166	Analysis of p53 Gene Alterations in Cancer: A Critical View. <i>Journal of Cellular Biochemistry</i> , 2007, 84, 255-292.		5
167	Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia via Data Mining Mutation Databases. <i>Frontiers in Oncology</i> , 2022, 12, 808886.	2.8	5
168	Monoclonal antibodies raised against <i>Xenopus</i> p53 interact with human p73. <i>Oncogene</i> , 2002, 21, 1304-1308.	5.9	4
169	TP53 and 53BP1 Reunited. <i>Trends in Cell Biology</i> , 2017, 27, 311-313.	7.9	4
170	Very low incidence of p53 antibodies in adult non-Hodgkin's lymphoma and multiple myeloma. <i>British Journal of Haematology</i> , 1998, 100, 184-186.	2.5	3
171	Prevalence, distribution and predictive value of <i>XPO1</i> mutation in a real-life chronic lymphocytic leukaemia cohort. <i>British Journal of Haematology</i> , 2020, 191, e90-e94.	2.5	3
172	The p53 tumor suppressor gene. <i>Advances in Genome Biology</i> , 1995, 3, 55-141.	0.3	2
173	A New Set of Monoclonal Antibodies Directed to Proline-Rich and Central Regions of p53. <i>Hybridoma</i> , 2004, 23, 287-292.	0.4	2
174	When mutant p53 plays hide and seek: a new challenge for diagnosis and therapy?. <i>Trends in Molecular Medicine</i> , 2009, 15, 1-4.	6.7	2
175	Cycle cellulaire et apoptose : le gène suppresseur de tumeur p53. <i>Medecine/Sciences</i> , 2000, 16, 469.	0.2	1
176	Ultra-Sensitive Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue Over a Century of Human Lifespan. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
177	<i>TP53</i> mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	1
178	The role of p53 in normal cells and in cancer development. <i>Pathologie Et Biologie</i> , 1997, 45, 781-4.	2.2	1
179	Detection and Sequencing of p53 Gene Mutations in Bronchial Biopsy Samples in Patients With Lung Cancer. <i>Chest</i> , 1994, 106, 1309-1310.	0.8	0
180	Génétique et cancer: aspects fondamentaux et cliniques. <i>Cancer Radiothérapie: Journal De La Societe Francaise De Radiothérapie Oncologique</i> , 2001, 5, 36s-41s.	1.4	0

#	ARTICLE	IF	CITATIONS
181	P53 (protein 53 kDa). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
182	TP53 (Tumour protein p53 (Li-Fraumeni syndrome)). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018, , .	0.1	0
183	Épidémiologie des cancers : de l'approche descriptive à la biologie moléculaire.. Medecine/Sciences, 2000, 16, 1397.	0.2	0
184	p53 Autoantibodies. , 1996, , 595-599.		0
185	Nouveaux modèles murins d'étude du gène suppresseur de tumeur p53. Medecine/Sciences, 1996, 12, 215.	0.2	0
186	La p53 : un ennemi public que l'on peut attaquer de tous les côtés. Medecine/Sciences, 1997, 13, 1339.	0.2	0
187	The p53 Tumor Suppressor Gene in Lung Cancer: From Molecular to Serological Diagnosis. , 1998, , 221-230.		0
188	P53 : un gène touché à tout dans les points de contrôle du cycle cellulaire après les lésions de l'ADN.. Medecine/Sciences, 1998, 14, 973.	0.2	0
189	Mdm2 et p53 : une association mortelle pour mieux préserver l'intégrité de l'ADN.. Medecine/Sciences, 1998, 14, 656.	0.2	0
190	The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants. Blood, 2019, 134, 3021-3021.	1.4	0
191	Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer. Chest, 1994, 106, 1309-10.	0.8	0
192	Analysis of p53 Gene Alterations in Cancer: A Critical View. , 2007, , 255-292.		0